Drug development advances in beneficial loss-of-function mutation targets validated by human genetics
Drug targets with human genetic evidence are more likely than those without to be clinically translatable and thus enter phase II/III clinical trials or be approved for marketing more quickly, which will likely significantly ...
Mar 26, 2024
0
0